Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2016-07-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01137-16PMID 27381389PMCID PMC4997883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?

  2016influential reference
• Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

  2015cited by this paper
• Small animal models for the study of Clostridium difficile disease pathogenesis.

  2014cited by this paper
• The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.

  2014cited by this paper
• Prospects for flavonoid and related phytochemicals as nature‐inspired treatments for Clostridium difficile infection

  2014cited by this paper
• Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile

  2013cited by this paper
• Structural basis of transcriptional pausing in bacteria.

  2013cited by this paper
• X-ray crystal structures of the Escherichia coli RNA polymerase in complex with benzoxazinorifamycins.

  2013cited by this paper
• In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy

  2012cited by this paper
• High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile.

  2012influential reference
• High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

  2009influential reference
• Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study

  2009cited by this paper
• Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

  2008influential reference
• Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin.

  2007cited by this paper
• Molecular Genetic and Structural Modeling Studies of Staphylococcus aureus RNA Polymerase and the Fitness of Rifampin Resistance Genotypes in Relation to Clinical Prevalence

  2006influential reference
• Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques

  2004cited by this paper
• In vitro Activity of Rifaximin, Metronidazole and Vancomycin against Clostridium difficile and the Rate of Selection of Spontaneously Resistant Mutants against Representative Anaerobic and Aerobic Bacteria, Including Ammonia-Producing Species

  2000cited by this paper

• Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.

  2025cites this paper
• Clostridioides difficile pathogenesis and control

  2025cites this paper
• Rifaximin resistance in Clostridioides difficile is associated with specific rpoB alleles and multilocus sequence typing (MLST) clades

  2025cites this paper
• Antimicrobial susceptibilities, resistance mechanisms and molecular characteristics of toxigenic Clostridioides difficile isolates in a large teaching hospital in Chongqing, China.

  2024cites this paper
• Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options

  2024cites this paper
• Clostridioides difficile Infection: Diagnosis and Treatment Challenges

  2024influential citation
• The vanRCd Mutation 343A>G, Resulting in a Thr115Ala Substitution, Is Associated with an Elevated Minimum Inhibitory Concentration (MIC) of Vancomycin in Clostridioides difficile Clinical Isolates from Florida

  2023cites this paper
• Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

  2022cites this paper
• Clostridioides difficile infection in Africa: A narrative review.

  2022cites this paper
• Detection and Genomic Characterisation of Clostridioides difficile from Spinach Fields

  2022cites this paper
• Mechanisms of antibiotic resistance of Clostridioides difficile.

  2021cites this paper
• A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile

  2021cites this paper
• Antibiotics resistance and mitigation strategies in healthcare settings: A scoping review

  2020cites this paper
• Antimicrobial resistance in Clostridium difficile ribotype 017

  2019cites this paper
• Characterisation of Clinical Clostridium difficile PCR Ribotype 002 Isolates from Different Time Lineages

  2019cites this paper
• Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.

  2019cites this paper
• Clostridium difficile in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014–2015

  2018cites this paper
• Effect of fluoroquinolone resistance mutation Thr-82→Ile on Clostridioides difficile fitness

  2018cites this paper
• Insights into RNA polymerase catalysis and adaptive evolution gained from mutational analysis of a locus conferring rifampicin resistance

  2017cites this paper
• University of Birmingham Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin

  2017cites this paper